Last reviewed · How we verify

Methyl Proscillaridin A — Competitive Intelligence Brief

Methyl Proscillaridin A (MEPROSCILLARIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

phase 2 Sodium/potassium-transporting ATPase subunit alpha-1 Other Small molecule Live · refreshed every 30 min

Target snapshot

Methyl Proscillaridin A (MEPROSCILLARIN). Methyl Proscillaridin A works by inhibiting the sodium/potassium-transporting ATPase subunit alpha-1.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Methyl Proscillaridin A TARGET MEPROSCILLARIN phase 2 Sodium/potassium-transporting ATPase subunit alpha-1
Digicor DIGITOXIN Eli Lilly marketed digitoxin Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1 1982-01-01
Uabaina ouabain marketed ouabain Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methyl Proscillaridin A — Competitive Intelligence Brief. https://druglandscape.com/ci/meproscillarin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing